OpenBit ResearchOpenBit
中文

What's driving Recursion Pharmaceuticals, Inc. Class A (RXRX)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Can Recursion convert its AI-native discovery engine into a funded clinical pipeline?

Why it matters now

The file concerns Recursion's own platform, clinical pipeline, partnership economics, and operating runway; changes in the thesis directly affect RXRX's pipeline valuation and revenue potential.

Next checkpoint

RXRX earnings (expected 2026-11-04)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to RXRX, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Clinical programs fail to advance or generate supportive data, regulatory study design cannot establish benefit, or operating resources and partnerships no longer support continued development.

Research drivers

  • Can Recursion convert its AI-native discovery engine into a funded clinical pipeline?

    Bullish · Cooling · Updated

    The supplied evidence favors continued pipeline advancement supported by clinical progress, partnership milestones, operating efficiencies, and cash runway, while clinical and regulatory execution remain unresolved.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • Recursion Pharmaceuticals reported five clinical-stage programs, including REC 4881 in FAP.

    Relayed by: Benzinga · Event date on record:

  • Recursion Pharmaceuticals expects the potential nomination of an oral INI development candidate with Sanofi.

    Relayed by: Benzinga · Event date on record:

  • Recursion Pharmaceuticals has lowered its 2026 full-year cash operating expense guidance to $375 million.

    Relayed by: Benzinga · Event date on record:

  • Recursion Pharmaceuticals ended the quarter with approximately $557 million in cash and equivalents and believes this provides an operating runway through early 2028.

    Relayed by: Benzinga · Event date on record:

  • Recursion's full-year OPEX guidance is 375, and the company expects to operate at that level.

    Relayed by: Benzinga · Ingestion date (event date unconfirmed):

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.